Rafael Holdings Inc Quick Ratio (RFL) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Rafael Holdings Inc  (NYSE: RFL)

Rafael Holdings Inc's Quick Ratio

RFL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 2.79 below Rafael Holdings Inc average.

Within Major Pharmaceutical Preparations industry 242 other companies have achieved higher Quick Ratio than Rafael Holdings Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 841 to 1023.

Explain Quick Ratio?
How much Cash & cash equivalents RFL´s has?
What are RFL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RFL Quick Ratio (Apr 30 2026)
Q3		 (Jan 31 2026)
2026		 (Oct 31 2025)
Q1		 (Jul 31 2025)
Q4		 (Apr 30 2025)
Q3
Y / Y Current Liabilities Change 5.63 % -31.45 % 65.95 % -31.45 % 37.46 %
Y / Y Cash & cash equivalent Change -19.61 % -21.75 % -16.13 % -21.75 % -47.59 %
Quick Ratio MRQ 2.79 4.85 3.79 4.85 3.66
RFL's Total Ranking # 1023 # 841 # 662 # 514 # 697
Seq. Current Liabilities Change 0.67 % -9.46 % 10.44 % 4.93 % -34.67 %
Seq. Cash & cash equivalent Change -42.21 % 15.88 % -13.7 % 39.1 % -43.75 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 243
Healthcare Sector # 413
Overall Market # 1023


Quick Ratio Statistics
High Average Low
60.65 15.26 0.45
(Apr 30 2018)   (Jul 31 2021)




Financial Statements
Rafael Holdings Inc's Current Liabilities $ 11 Millions Visit RFL's Balance sheet
Rafael Holdings Inc's Cash & cash equivalent $ 30 Millions Visit RFL's Balance sheet
Source of RFL's Sales Visit RFL's Sales by Geography


Cumulative Rafael Holdings Inc's Quick Ratio

RFL's Quick Ratio for the trailling 12 Months

RFL Quick Ratio

 (Apr 30 2026)
12 Months		 (Jan 31 2026)
12 Months		 (Oct 31 2025)
12 Months		 (Jul 31 2025)
12 Months		 (Apr 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -9.37 % -5.12 % 49.8 % 67.58 % 287.23 %
Y / Y Cash & cash equivalent TTM Growth -20.05 % -27.73 % -25.48 % -8.52 % -6.92 %
Quick Ratio TTM 4.06 4.28 4.15 4.79 4.6
Total Ranking TTM # 3737 # 3114 # 3013 # 2850 # 2655
Seq. Current Liabilities TTM Growth 1.32 % -10.16 % 10.76 % -10.12 % 6.07 %
Seq. Cash & cash equivalent TTM Growth -3.94 % -7.2 % -4.12 % -6.46 % -13.17 %

Quick ratio ranking by company, industry and sector >> Back to RFL Financial Strength Comparisons >> Go to Compare RFL Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $10.95 millions, cumulative Quick Ratio decreased to 4.06 below the Rafael Holdings Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 424 other companies have achieved higher Quick Ratio than Rafael Holdings Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the from 3114 to 3737.

Explain Quick Ratio?
How much Cash & cash equivalents RFL´s has?
What are RFL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 425
Healthcare Sector # 866
Within the Market # 3737


trailing twelve months Quick Ratio Statistics
High Average Low
40.84 10.27 0.67
(Oct 31 2023)   (Jul 31 2021)




Companies with similar Quick Ratio in the quarter ending Apr 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioApr 30 2026 MRQ Cash & cash equivalentApr 30 2026 MRQ Current Liabilities
Centessa Pharmaceuticals Plc  7.56 $ 276.589  Millions$ 36.574  Millions
Adicet Bio Inc   7.52 $ 137.592  Millions$ 18.298  Millions
Cartesian Therapeutics Inc   7.44 $ 118.641  Millions$ 15.945  Millions
Q32 Bio Inc   7.36 $ 50.751  Millions$ 6.892  Millions
Ibio inc   7.32 $ 47.641  Millions$ 6.504  Millions
Anaptysbio Inc   7.24 $ 286.455  Millions$ 39.582  Millions
Avalo Therapeutics Inc   7.08 $ 82.140  Millions$ 11.599  Millions
Alx Oncology Holdings Inc  6.95 $ 140.324  Millions$ 20.178  Millions
Lyell Immunopharma Inc   6.88 $ 254.023  Millions$ 36.947  Millions
Zymeworks Inc   6.85 $ 244.282  Millions$ 35.649  Millions
Telomir Pharmaceuticals Inc   6.72 $ 5.561  Millions$ 0.827  Millions
Biohaven Ltd   6.68 $ 347.817  Millions$ 52.075  Millions
Silence Therapeutics Plc  6.63 $ 90.590  Millions$ 13.668  Millions
Dermata Therapeutics Inc   6.60 $ 6.945  Millions$ 1.053  Millions
Azitra Inc   6.49 $ 10.051  Millions$ 1.550  Millions
Sionna Therapeutics Inc   6.48 $ 63.324  Millions$ 9.776  Millions
Assembly Biosciences Inc   6.47 $ 226.601  Millions$ 34.997  Millions
Renovorx Inc   6.44 $ 12.362  Millions$ 1.920  Millions
Opus Genetics Inc   6.42 $ 59.959  Millions$ 9.340  Millions
Amarin Corp Plcuk  6.40 $ 308.023  Millions$ 48.153  Millions
Briacell Therapeutics Corp   6.35 $ 22.804  Millions$ 3.590  Millions
Grace Therapeutics Inc  6.35 $ 16.977  Millions$ 2.673  Millions
Annexon Inc   6.26 $ 225.025  Millions$ 35.937  Millions
Tonix Pharmaceuticals Holding Corp   6.26 $ 185.470  Millions$ 29.647  Millions
Arcturus Therapeutics Holdings Inc   6.15 $ 211.375  Millions$ 34.369  Millions
Zentalis Pharmaceuticals Inc   6.01 $ 211.758  Millions$ 35.236  Millions
Camp4 Therapeutics Corporation  5.97 $ 99.209  Millions$ 16.624  Millions
Rocket Pharmaceuticals Inc   5.90 $ 144.379  Millions$ 24.466  Millions
Bridgebio Oncology Therapeutics Inc   5.83 $ 252.275  Millions$ 43.260  Millions
Actinium Pharmaceuticals Inc  5.73 $ 42.132  Millions$ 7.349  Millions

Date modified: 2026-09-26T07:34:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.